Insider Selling: Exelixis, Inc. (EXEL) VP Sells 1,560 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 1,560 shares of the firm’s stock in a transaction on Wednesday, January 9th. The shares were sold at an average price of $23.50, for a total value of $36,660.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Patrick J. Haley also recently made the following trade(s):

  • On Monday, January 7th, Patrick J. Haley sold 5,560 shares of Exelixis stock. The shares were sold at an average price of $21.51, for a total value of $119,595.60.
  • On Wednesday, January 9th, Patrick J. Haley sold 9,120 shares of Exelixis stock. The shares were sold at an average price of $22.18, for a total value of $202,281.60.
  • On Thursday, January 3rd, Patrick J. Haley sold 8,000 shares of Exelixis stock. The shares were sold at an average price of $19.95, for a total value of $159,600.00.
  • On Wednesday, November 7th, Patrick J. Haley sold 20,000 shares of Exelixis stock. The shares were sold at an average price of $17.32, for a total value of $346,400.00.

Shares of EXEL opened at $24.07 on Friday. The stock has a market cap of $7.08 billion, a price-to-earnings ratio of 47.20, a P/E/G ratio of 1.46 and a beta of 2.09. Exelixis, Inc. has a 12 month low of $13.42 and a 12 month high of $31.79. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.54 and a current ratio of 8.66.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Thursday, November 1st. The biotechnology company reported $0.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.22. The firm had revenue of $225.40 million for the quarter, compared to the consensus estimate of $174.14 million. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The business’s quarterly revenue was up 47.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.26 EPS. On average, equities research analysts forecast that Exelixis, Inc. will post 1.3 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in EXEL. BlackRock Inc. raised its position in shares of Exelixis by 3.8% in the 3rd quarter. BlackRock Inc. now owns 30,094,004 shares of the biotechnology company’s stock worth $533,265,000 after acquiring an additional 1,096,629 shares in the last quarter. Vanguard Group Inc. increased its position in Exelixis by 3.2% in the 3rd quarter. Vanguard Group Inc. now owns 26,527,089 shares of the biotechnology company’s stock valued at $470,060,000 after buying an additional 834,478 shares in the last quarter. Vanguard Group Inc increased its position in Exelixis by 3.2% in the 3rd quarter. Vanguard Group Inc now owns 26,527,089 shares of the biotechnology company’s stock valued at $470,060,000 after buying an additional 834,478 shares in the last quarter. JPMorgan Chase & Co. increased its position in Exelixis by 8.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,931,216 shares of the biotechnology company’s stock valued at $105,101,000 after buying an additional 480,986 shares in the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd increased its position in Exelixis by 27.1% in the 3rd quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 4,666,961 shares of the biotechnology company’s stock valued at $82,698,000 after buying an additional 995,133 shares in the last quarter. 77.22% of the stock is currently owned by hedge funds and other institutional investors.

EXEL has been the topic of several recent research reports. BidaskClub downgraded Exelixis from a “sell” rating to a “strong sell” rating in a report on Friday, September 14th. Goldman Sachs Group initiated coverage on Exelixis in a report on Monday, September 17th. They set a “neutral” rating and a $22.00 price objective on the stock. Guggenheim initiated coverage on Exelixis in a report on Monday, September 17th. They set a “buy” rating on the stock. Oppenheimer set a $40.00 price objective on Exelixis and gave the company a “buy” rating in a report on Thursday, November 1st. Finally, Piper Jaffray Companies cut their price objective on Exelixis from $29.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $28.38.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by WKRB News and is owned by of WKRB News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.wkrb13.com/2019/01/11/insider-selling-exelixis-inc-exel-vp-sells-1560-shares-of-stock.html.

Exelixis Company Profile

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

See Also: What does the Dow Jones Industrial Average (DJIA) measure?

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply